RESUMEN
Eosinophilic granulomatosis with polyangiitis (EGPA) is a small- to medium-vessel necrotising vasculitis and eosinophilic inflammation. Mepolizumab, an anti-interleukin-5 (IL-5) monoclonal antibody has been approved in Japan since 2018 for refractory EGPA treatment. Benralizumab, an anti-IL-5 receptor monoclonal antibody, also has been reported to reduce the glucocorticoid dose in patients with refractory EGPA. On the other hand, several investigators have demonstrated new-onset EGPA under biologics, and it is unclear whether this treatment for severe allergic diseases can prevent the development of EGPA. Herein, we report a case of new-onset EGPA under benralizumab treatment. The patient had fever, weight loss, muscle pain, and paraesthesia, the serum eosinophil count was 0/µL, and the biopsy showed necrotizing vasculitis without eosinophilic infiltration. She was diagnosed as having EGPA and treated with high-dose glucocorticoid and intravenous cyclophosphamide, with a good response. Our case report indicates that anti-IL-5 agents may mask the development of EGPA and clinicians should be aware of the development of EGPA during anti-IL-5 agents.
Asunto(s)
Síndrome de Churg-Strauss , Eosinofilia , Granulomatosis con Poliangitis , Femenino , Humanos , Síndrome de Churg-Strauss/complicaciones , Síndrome de Churg-Strauss/diagnóstico , Síndrome de Churg-Strauss/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Granulomatosis con Poliangitis/complicaciones , Granulomatosis con Poliangitis/diagnóstico , Granulomatosis con Poliangitis/tratamiento farmacológico , Eosinofilia/diagnóstico , Eosinofilia/tratamiento farmacológico , Eosinofilia/etiologíaRESUMEN
Coronavirus disease 2019 (COVID-19) has spread worldwide since 2019, and mRNA vaccines for the disease have been rapidly delivered to limit the severity of infection. However, while these vaccines are effective in reducing the morbidity and severity of the disease, some patients develop severe adverse drug reactions and new-onset autoimmune phenomena, such as myocarditis, thrombosis with thrombocytopenia, and vasculitis. In addition, some patients develop arthritis following vaccination, including rheumatoid arthritis (RA). We herein report a case of new-onset seropositive RA following COVID-19 mRNA vaccination. Although tests for rheumatoid factor and anti-cyclic citrullinated peptide antibody had been negative three years before vaccination, the patient developed seropositive RA following COVID-19 mRNA vaccination.
Asunto(s)
Artritis Reumatoide , Vacunas contra la COVID-19 , COVID-19 , Humanos , Artritis Reumatoide/complicaciones , Artritis Reumatoide/tratamiento farmacológico , COVID-19/prevención & control , Vacunas contra la COVID-19/efectos adversos , Factor Reumatoide , ARN Mensajero , Vacunación/efectos adversosRESUMEN
We herein report a case of Behçet's disease with renal infarction due to mucormycosis. A 76-year-old man with entero-Behçet's disease had been treated with glucocorticoid and tumor necrosis factor (TNF) inhibitors. His entero-Behçet's disease was refractory to these treatments, and ileocecal resection was performed. After the operation, renal infarction that was unresponsive to anticoagulation therapy developed. He ultimately died of renal failure due to renal infarction. At the autopsy, histopathology of abundant hyphae in the renal vessel wall revealed mucormycosis. Renal mucormycosis is an important cause of renal failure with renal infarction in immunocompromised patients.
Asunto(s)
Síndrome de Behçet , Mucormicosis , Anciano , Síndrome de Behçet/complicaciones , Síndrome de Behçet/diagnóstico , Glucocorticoides , Humanos , Infarto/etiología , Masculino , Mucormicosis/complicaciones , Mucormicosis/diagnóstico , Inhibidores del Factor de Necrosis TumoralRESUMEN
Oxidation of the facial-type trichloridoruthenium(III) complex bearing ethylbis(2-pyridyl-methyl)amine (ebpma), fac-[Ru(III)Cl3(ebpma)], with an equimolecular amount of (NH4)2[Ce(IV)(NO3)6] in acetonitrile afforded a ligand-based oxidation product of an acetonitriledichloridoruthenium(III) complex having bis(2-pyridylcarbonyl)aminato (bpca), [Ru(III)Cl2(NCCH3)(bpca)]. The complex changed into a trichloridoruthenium(III) complex by a reaction with hydrochloric acid and the triacetonitrileruthenium(II) complex by reduction with Zn in ethanol-acetonitrile. The bpca moiety showed interactions with cations such as protons.